Independent
Tenure on this board
0.3 yrs
Also a director at
Tectonic Therapeutic Inc (TECX)
Meeting calendar
PTCT · Annual meeting · Tuesday, June 2, 2026
Ptc Therapeutics Inc
4 nominees · 3 ballot items.
Election of four Class I directors; Ratification of Ernst & Young LLP as independent auditor; Advisory (non-binding) vote to approve named executive officer compensation.
Market cap
$6.5B
1Y TSR
+70.6%
Board grade
B
Record date
Apr 10, 2026
Filing
DEF 14A
Meeting concluded · Jun 2, 2026
Follow how the vote landed and what changed on Ptc Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect four Class I director nominees (Jessica Chutter, Matthew B. Klein, Stephanie S. Okey and Jerome B. Zeldis) each for a three-year term ending in 2029.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
- 3
Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation paid to the company's named executive officers as disclosed in the proxy statement.
More detail
Proposal asks stockholders to approve, on a non-binding advisory basis, the Company’s 2025 named executive officer compensation as disclosed in the proxy materials. Management seeks endorsement of its compensation approach, which emphasizes a high proportion of at-risk compensation tied to company performance (annual cash incentives and equity awards) and includes performance-based PSUs for the CEO tied to relative TSR versus the Nasdaq Biotechnology Index. The board recommends a “for” vote as governance best practice to receive feedback from shareholders; the Compensation Committee will consider the outcome when setting future pay. Key context: the Company delivered strong 2025 operational and financial results (revenue above guidance, multiple regulatory approvals and launches), leading to a 145% corporate rating for 2025 cash incentives and a high say-on-pay support (96.8% in 2025). The vote is advisory only and does not change compensation directly, but provides important input to the board. The compensation program includes double-trigger change-in-control protection and clawback policies; the board believes alignment with peers and pay-for-performance principles support shareholder value.
Director elections
Nominees on the ballot4
Not independent
Tenure on this board
3.3 yrs
Also a director at
Clearpoint Neuro Inc (CLPT)
Independent
Tenure on this board
7.6 yrs
Also a director at
Crinetics Pharmaceuticals Inc (CRNX)
Independent
Tenure on this board
13.9 yrs
Also a director at
Soligenix Inc (SNGX)Nexgel Inc (NXGL)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.9% | 9,031,564 | $615M |
| 2 | RTW INVESTMENTS, LP | 9.3% | 7,746,415 | $528M |
| 3 | JANUS HENDERSON GROUP PLC | 8.5% | 7,034,622 | $479M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8% | 4,804,594 | $327M |
| 5 | STATE STREET CORP | 5.2% | 4,346,519 | $296M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 3,676,256 | $250M |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 4.1% | 3,414,356 | $233M |
| 8 | TORONTO DOMINION BANK | 3.6% | 3,025,945 | $206M |
| 9 | BlackRock, Inc. | 2.9% | 2,434,636 | $166M |
| 10 | ARMISTICE CAPITAL, LLC | 2.5% | 2,074,449 | $141M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Ptc Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Ptc Therapeutics Inc 2026 annual meeting?
- Ptc Therapeutics Inc (PTCT) holds its 2026 annual shareholder meeting on Tuesday, June 2, 2026.
- What is the record date for the Ptc Therapeutics Inc 2026 meeting?
- The record date for the Ptc Therapeutics Inc 2026 meeting is Friday, April 10, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Ptc Therapeutics Inc's 2026 meeting?
- The board is presenting 4 director nominees at the Ptc Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Ptc Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Ptc Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.